Captor Therapeutics is a biopharmaceutical company focused on development of protein degradation drugs for cancer and autoimmune diseases, which have limited or no known treatment options.

Targeted Protein Degradation (TPD) combats the therapeutic limits of small molecules with overcoming drug resistance and uncoupling their pharmacokinetics from pharmacodynamics. Breakthrough TPD technology allows degradation of virtually any intracellular protein including the so-called "undruggable proteome".

Captor Therapeutics is a Swiss-Polish company. Captor GmbH entity operates in Basel, the pharma hub of Switzerland, providing excellent opportunities for business development, while our state-of-the-art laboratories are located in Wroclaw, Poland. Our integrated competencies and expertise in biology and chemistry allow us to perform all stages of early drug development.